演題抄録

International Session(Poster)

開催概要
開催回
第51回・2013年・京都
 

Predicting recurrence and progression in NMIBC using EORTC risk tables

演題番号 : ISP-27

[筆頭演者]
Pawan Raj Chalise:1 
[共同演者]
Bhoj Raj Luitel:1、Sidharth Sidharth:1、Uttam K Sharma:1、Prem R Gyawali:1、Guna K Shrestha:1、Bhola Raj Joshi:1

1:Urology Unit, Department of Surgery, TU Teaching Hospital, Nepal

 

Background: The EORTC risk table is a nomogram constructed to predict the probability of recurrence and progression in patients treated for NMIBC and this study was conducted to predict the recurrence and progression in Nepalese patients.Methods: A prospective observational study was conducted over a period of 3 years. Forty six patients with NMIBC who underwent TURBT and completed two year follow up were included, and their predictive first and second year recurrence and progression were recorded. The patients were stratified into low, intermediate and high risk categories. Low risk patients were kept in surveillance, while intermediate and high risk patients received intravesical Mitomycin-C and BCG respectively. The actual recurrence and progression rates were noted and compared to the predictive scores.Results: Among the 46 patients, 6 (13%) had recurrence and 1 (2.2%) had progression at one year. The two years recurrence and progression rate were 17.4% and 2.2%. When the patients were stratified into risk categories, 7 (15.2%) fall into low, 15 (32.6%) were in intermediate and 24 (52.2%) were in high risk category. The first year and second year recurrence rate in intermediate group were 13.3% and 20%. The risk reductions as compared to EORTC predicted risk for recurrence were 53.6% and 49.6%. We found that Mitomycin-C was well tolerated by patients with no major side effects. Four patients (16.7%; 4/24) in high risk category had recurrence at one year while another one had recurrence in 2nd year (20.8%; 5/24). The risk reductions for recurrence in high risk category were 58.3% and 60.1%. Three patients who received intravesical BCG developed severe cystitis and 3 other refused maintenance schedule due to severe bladder related symptoms.Conclusion: The EORTC risk table is a simple tool to predict the recurrence and progression in NMIBC. Mitomycin-C is well tolerated but weak in preventing recurrence while BCG is more effective in preventing recurrence.

前へ戻る